No Data
No Data
Saisheng Pharmaceutical announced that the 44,500 share options granted have been exercised
Saisheng Pharmaceutical (06600) issued an announcement on May 22, 2024, according to the rules of the initial public offering after-sales share option plan: 7,500 share options granted under the initial public offering after-sales share option plan have expired; and the 44,500 share options granted under the initial public offering after-sales share option plan have been exercised.
Saisheng Pharmaceutical (06600): 44,500 share options have been exercised
According to the Zhitong Finance App, Saisheng Pharmaceutical (06600) issued an announcement on May 22, 2024, according to the rules of the initial public offering after-sales share option plan: 7,500 share options granted under the initial public offering after-sales share option plan have expired; and 44,500 share options granted under the initial public offering after-sales share option plan have been exercised.
Saisheng Pharmaceutical (06600): 40,000 share options have been exercised
According to the Zhitong Finance App, Saisheng Pharmaceutical (06600) announced that on May 20, 2024, the 40,000 share options granted under the initial public offering after-sales share option plan have been exercised in accordance with the rules of the initial public offering after-sales share option plan.
A record high! The total number of clinical trials exceeded 4,000 in 2023
According to the report, in 2023, the total number of clinical trials registered on the drug clinical trial registration and information disclosure platform surpassed 4,000 for the first time, reaching 4,300 (in terms of CTR), the highest total number of registrations in history, an increase of 26.1% over the total number of registrations in 2022.
Saisheng Pharmaceutical announced that the 20,000 share options granted have been exercised
Saisheng Pharmaceutical (06600) announced that on May 16, 2024, 20,000 share options granted under the initial public offering after-sales share option plan have been exercised in accordance with the rules of the initial public offering after-sales share option plan.
Saisheng Pharmaceutical (06600): 20,000 share options have been exercised
Saisheng Pharmaceutical (06600) issued an announcement. On May 16, 2024, according to the initial public offering after-sales share purchase options...
No Data